LIVE
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines,. Track GlaxoSmithKline Pharmaceuticals Limited's live NSE:GLAXO share price ₹2,659.50 (+0.34%), market cap ₹₹451B, P/E 43.5. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for GLAXO — real-time NSE India stock intelligence.
Open
₹2,665.40
High
₹2,665.40
Low
₹2,630.00
Prev. Close
₹2,650.50
52W High
₹2,936.00
52W Low
₹2,088.10
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines,
Key Takeaway
GlaxoSmithKline Pharmaceuticals Limited is rated none with a P/E of 43.5x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is GlaxoSmithKline Pharmaceuticals Limited fairly valued right now?
Because a P/E of 43.5x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting GlaxoSmithKline Pharmaceuticals Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
995 Cr
Revenue
278 Cr
Net Profit
49.1%
ROE
0%
ROCE
61.07
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 3,226 | 3,442 | 3,726 | 3,808 | 3,815 |
| Net Profit | 611 | 590 | 928 | 1,036 | 1,042 |
| ROE (%) | — | — | — | 49.1% | 49.1% |
| EPS (₹) | — | — | — | 61.07 | 61.07 |
| Debt/Equity | — | — | — | 1.5 | 1.5 |